FDA: Preliminary Data Shows Possible Higher Death Risk From Paclitaxel Devices
SILVER SPRING, Md. — The Food and Drug Administration on March 15 said a preliminary review of data has identified a potential “signal” of higher deaths among patients who were treated...To view the full article, register now.
Already a subscriber? Click here to view full article